retinoic acid early transcript 1K (pseudogene)Genealiases: []
Q-omics provides the consensus-scored RAET1K profile across patient tissues and cancer cell-line models. RAET1K expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RAET1K is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, RAET1K RNA expression shows 16,264 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where RAET1K shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAET1K — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAET1K survival associations across molecular data types. RAET1K RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAET1K RNA expression–survival associations across cancer types. High RAET1K expression shows unfavorable associations in UVM, KIRP, KIRC, ACC, MESO and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RAET1K RNA expression.
This table summarizes RAET1K tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RAET1K. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAET1K shows higher tumor expression in HNSC, KIRC, BLCA, THCA, STAD and LUAD. The HNSC box plot shows higher RAET1K RNA expression in tumor versus normal tissue (log2 FC = +0.785, t-test p < 0.001).
This table shows molecular features associated with RAET1K in patient tissues and cancer cell lines. In patient samples, RAET1K shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAET1K RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY.
